Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

Marker Therapeutics Appoints Steve Elms to its Board of Directors

PR Newswire August 6, 2019

Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR

PR Newswire July 20, 2019

Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma

PR Newswire July 17, 2019

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma

PR Newswire June 20, 2019

Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results

PR Newswire May 9, 2019

Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference

PR Newswire May 7, 2019

TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing

PR Newswire October 17, 2018

TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

PR Newswire October 10, 2018

TapImmune to Present at Two Upcoming Investor Conferences

PR Newswire September 25, 2018

TapImmune To Present at 2018 Janney Healthcare Conference

PR Newswire September 12, 2018

TapImmune to Participate at Two Upcoming Industry Conferences

PR Newswire August 29, 2018

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Tapimmune, Inc. - TPIV

PR Newswire August 3, 2018

TapImmune Announces Pricing of $70 Million Private Placement

PR Newswire June 8, 2018

28 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  May 31, 2018

TapImmune to Present at the Jefferies 2018 Global Healthcare Conference

PR Newswire May 31, 2018

TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum

PR Newswire May 30, 2018

TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center

PR Newswire May 22, 2018

TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform

PR Newswire May 16, 2018

TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics

PR Newswire May 15, 2018

TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

PR Newswire May 15, 2018